The randomized clinical trial of implantable drug delivery systems (IDDS) plus comprehensive medical management (CMM) versus CMM alone showed better clinical success at 4 weeks for IDDS patients. This 'as treated' analysis assessed if improvements in pain control, drug toxicity and survival were maintained over time. At 12 weeks the IDDS VAS pain scores decreased from 7.81 to 3.89 (47% reduction) compared with 7.21 to 4.53 for non-IDDS patients (42% reduction; P = 0.23). The 12 week drug toxicity scores for IDDS patients decreased from 6.68 to 2.30 (66% reduction), and for non-IDDS patients from 6.73 to 4.13 (37% reduction; P = 0.01). All individual drug toxicities improved with IDDS at both 4 and 12 weeks. At 6 months, only 32% of the group randomized to CMM and who did not cross over to IDDS were alive, compared with 52% -59% for patients in those groups who received IDDS. Conclusions: IDDS improved clinical success, reduced pain scores, relieved most toxicity of pain control drugs, and was associated with increased survival for the duration of this 6 month trial.
Introduction
Most cancer patients achieve good pain relief with acceptable side-effects, but 14% do not, even when treated by experts according to the World Health Organization guidelines [1] . The Cancer Pain Trial was a multicenter, multinational randomized controlled study to evaluate the clinical effectiveness of intrathecal pain therapy with a programmable, implantable drug delivery system (IDDS) supplemented with comprehensive medical management (CMM), compared with CMM alone [2] . All patients had refractory cancer pain with Visual Analogue Scores (VAS) for pain >5, despite treatment with at least 200 mg of morphine oral equivalent daily dose (MOED), or opioid toxicity that precluded drug escalation. At the primary study time point, 4 weeks after randomization, clinically significant reductions in pain relief were achieved in patients randomized to both IDDS (52%) and CMM (39%), and therapy was more successful in patients randomized to the IDDS. The most striking benefit was the significant reduction in opioid side-effects in patients assigned to IDDS (50%) compared with CMM (17%).
This pre-planned analysis was conducted to determine if relief from pain and drug toxicity was sustained after the first 4 weeks, how long it was sustained, and to define the impact of the interventions as treated.
Patients and methods
The methods of the trial have been described in detail [2] , therefore a summary is given in Table 1 .
Patients were eligible if they had documented cancer, VAS pain scores consistently > _ 5/10 despite pain management by their oncologist, were on at least 200 mg of oral morphine or the equivalent, and had at least 3 months to live. Patients were randomly assigned to CMM or intrathecal pain therapy (IDDS) delivered by a programmable infusion system (SynchroMed e Infusion System, Medtronic, Inc., Minneapolis, MN). Allocation was central by telephone, concealed, and stratified by center in permuted small blocks of either two or four patients. Data were recorded at baseline, 2, 4, 6, 8, 10 and 12 weeks, and then monthly to 6 months.
The primary evaluation of clinical effectiveness was done 4 weeks after randomization by comparing the Visual Analog Scale (pain today on a 0-10 continuous scale ranging from no pain to the worst pain imaginable) and the composite drug toxicity score, the sum of 15 individual drug toxicity scores (0-4) selected before the trial. These were measured by the Common Toxicity Criteria (CTC) used by the National Cancer Institute (NCI) for all cooperative group clinical trials for the measurement of drug-related side-effects, available at the NCI website (http://ctep. info.nih.gov/CTC3/default.htm). Comprehensive medical management of pain and toxicity in both study arms was done by the algorithms described in Management of Cancer Pain: A Quick Reference Guide for Clinicians [3] . Those assigned to the CMM group received all pain therapy except spinally administered drugs, cordotomy, or other similar neurosurgical interventions. Those who received IDDS started with morphine but could receive other analgesics if morphine proved to be inadequate for pain relief, using specified algorithms. Crossover was allowed for clinical failure (VAS pain score persistently >5 despite maximum tolerated drug dosages) after consultation with one of the lead investigators (T.J.S. or P.S.) to ensure consistent determination that pain was not being adequately controlled and that reasonable modalities had been tried. Other treatments such as radiation for palliation, chemotherapy for palliation, bisphosphonates, etc. were allowed, and were equally distributed across the study arms.
To analyze the results of sustained treatment, as in the primary study analysis, the primary outcome was the difference in number of patients receiving clinically successful and effective pain treatment [ > _ 20% improvement in either pain VAS or composite drug-related toxicity using NCI CTC]. The 'as treated' analyses presented here were Design Randomized controlled study of 200 patients assigned to each of two groups: CMM following standard guidelines (100 patients) and IDDS+ CMM (100 patients). Allocation was concealed, and randomization was done in blocks of two and four to ensure that each center treated all types of patient. Crossover to IDDS was allowed if patients had unrelieved pain or drug toxicity, with central approval by T.S. or P.S.; all patients received CMM so there was no crossover from IDDS plus CMM to CMM alone. The study was designed to have a 90% statistical power to detect a 20% change in pain scores. CMM was done using published guidelines in Management of Cancer Pain: A Quick Reference Guide for Clinicians [3] . Objectives Primary objective: to evaluate clinical success (an improvement of 20% in pain or symptom control) with differences between study arms in changes in pain and opioid side-effects, using 0-10 pain VAS and NCI Common Toxicity Criteria (CTC) scores to evaluate end points. The measurement point for primary objective was 4 weeks after randomization. For this study, measurements are reported for all patients alive at 12 weeks. Secondary objectives: pain scores over time (comparison of changes in VAS for pain over the duration of the trial); drug side-effects over time (comparison of changes in drug side-effects and pain relief over the duration of the follow-up period). The NCI CTC standardizes the comparison of drug-related adverse events in clinical studies. Fifteen specific opioid toxicities were measured with scales extracted from the CTC. A 'comprehensive toxicity score' was calculated by summing the grades of all the specific toxicities for each patient at each follow-up visit. Overall survival was represented using Kaplan-Meier curves.
Center and investigator criteria Twenty-one centers, 16 in the US, one in Australia and four in Europe (8 main centers). Investigators at sites with established pain clinics or pain treatment departments. Prior experience implanting and managing IDDS. Participants at each site must include both a pain control specialist and an oncologist.
Patient selection criteria Patients with intractable cancer-associated pain expected to survive a minimum of 3 months or more, VAS score > _ 5/10, and willing to give informed consent. Pain therapy prior to randomization of opiate doses > _ 200 mg/day oral morphine or the equivalent (MOED), or lower doses with unacceptable side-effects.
planned in the original protocol. 'As randomized' comparisons are not presented as the crossover rate and the reduction in sample size due to deaths from advanced disease make them of little practical use.
Results were analyzed by two main groups. The 'IDDS' group included patients implanted after randomization to the IDDS arm ('IDDS/implant', n = 73), and those assigned to the CMM arm who were implanted after failure of assigned therapy ('CMM/implant', n = 30). The 'non-IDDS' group included both patients assigned to the CMM arm ('CMM/no implant', n = 69), and those who were randomized to IDDS but did not receive an implant ('IDDS/no implant', n = 28).
Crossover was explicitly allowed in the trial, as IDDS is a Food and Drug Administration (FDA)-approved device with multiple cohort studies documenting efficacy [4] and its use could not be ethically withheld.
Alternative study designs, such as placement of a 'sham' pump, or placebo in the IDDS after the patient had already experienced relief by an intraspinal trial prior to IDDS implant, were also rejected as unethical in this vulnerable population.
The pain and VAS scores were adjusted using multiple linear regression models that included adjustments for candidate baseline factors to control for differences in these patient groups, after reassignment from the well balanced randomization groups to the new groups based on treatment actually received. The final model used to evaluate VAS scores included the baseline score, and the treatment received during the first 4 weeks. The model for the 12-week analysis also included whether chemotherapy had been administered previously. The final model for drug toxicity scores at both the 4-week and 12-week intervals included only the baseline score and the treatment actually received. The reduction in scores for both VAS and drug toxicity are from the adjusted linear models and not an exact subtraction of the baseline and follow-up values.
A P-value of 0.05 was predetermined as significant, and all tests are two-tailed. The authors had full access to all the data in the study and T.S. Number of adjunctive medications The values presented are medians and (25th percentile to 75th percentile). d The added scores of all the toxicity scales measured that were related to the treatment. The maximum would be 4Â15 scales or 60; the minimum would be 0.
takes responsibility for the integrity of the data and the accuracy of the data analysis.
Results
Both randomized study arms were well balanced at baseline with respect to patient demographic characteristics, cancer treatment history, pain and pain treatment history, as shown in Table 2 . The differences between the 'as treated' groups that were adjusted with multiple linear regression models before statistical comparisons are shown in detail. None of the differences are significantly different. Small 5%-10% differences in the type of cancer or Eastern Cooperative Oncology Group (ECOG) performance status are not likely to be large enough to change results. Figure 1 shows the patient disposition between randomization and 6-month follow-up. Of the 56 patients remaining in the CMM arm at 12 weeks, 19 had received IDDS system implants. A total of 11 of the original 99 patients in the group had withdrawn from the trial, two had been lost to follow-up, and 30 had died. Of the 57 IDDS patients remaining in the trial at 12 weeks, 12 had not received a pump. A total of 12 of the original 101 patients in the group had withdrawn from the trial, one had been lost to follow-up, and 21 had died. Of the original 200 patients randomized into the trial, 76 survived to the 6-month follow-up. Of these, 45 had received IDDS implants and 31 had not.
The primary study end point results are shown in Table 3 . Clinically successful pain management, minimally defined as a 20% reduction of either pain or toxicity, was significantly (P = 0.02) more frequent with IDDS at 4 weeks. By 12 weeks, the differences between IDDS and non-IDDS groups had narrowed, as 22 of 30 of the most refractory CMM patients had received IDDS implants, raising the values of the remaining CMM group and lowering the values of the IDDS group. By 12 weeks, 78% -82% of surviving patients had achieved a > _ 20% reduction in pain or drug toxicity. The IDDS group more often achieved a > _ 20% reduction of both pain and opioid side-effects at both 4 weeks (P = 0.0003) and 12 weeks (P = 0.01). The IDDS patients had significantly more relief of both pain and drug toxicity at 4 weeks, which was sustained throughout the full 12-week period. Pain scores were significantly better at 4 weeks with IDDS (P = 0.002), but this difference narrowed by 12 weeks (P = 0.23) for the reasons noted above. Of note, both groups achieved pain relief with pain scores reduced by 47% in those in the IDDS arm, and 42% in those who remained in the non-IDDS arm. The results are shown graphically in Figure 2 .
Drug toxicity scores were significantly better at 4 weeks with IDDS, which was sustained for the 12-week period (P = 0.01). The difference between IDDS and non-IDDS is significant at both 4 weeks (P = 0.0003) and 12 weeks (P = 0.01). The results are shown in Figure 3 . Figure 4A and B shows the reduction in individual toxicities from baseline to 4 weeks and from baseline to 12 weeks. At 4 weeks, all measured toxicities had larger reductions in the IDDS treatment group than the CMM arm, and 7 of 15 individual reductions were statistically significantly greater (P = 0.05). At 12 weeks, even though the composite toxicity score was significantly lower in IDDS-treated patients, no individual toxicity was significantly different to the others, due to the crossover of the most refractory patients from CMM to IDDS.
IDDS reduced pain VAS and drug toxicity scores significantly, even in patients with the worst, most refractory painthose who had been failed by CMM. As shown in Table 4 , at crossover the average pain VAS was 6.2 and average toxicity score 7.6 despite an escalation of opioid doses from a baseline median MOED of 320 mg with one or more adjuvant drugs. (Opioid dose adjustment, rotation or switching to improve pain control and reduce opioid side-effects was required before CMM therapy could be considered to have failed and IDDS implant was allowed, after consultation with either T.S. or P.S.) After implant, the pain VAS was reduced from 6.2 to 4.5 (27% reduction; P = 0.01), and the drug toxicity score from 7.6 to 3.8 (50% reduction; P <0.01). These reductions were similar to the group initially randomized to IDDS. The median survival after IDDS implant was 101 days.
Survival at 6 months is shown in Figure 5 . At 6 months, survival by group was IDDS/implant 54.3%, IDDS/no implant 59.2%, CMM/implant 51.8%, and CMM/no implant 31.5%. Median survival in the CMM/no implant group was 121 days. Over half of patients in all other groups were still alive 6 months after entry in the trial.
As reported in abstract form [5] for a subgroup of US patients (for whom costs and practice patterns would most likely be similar), the total mean costs, as treated, were US$22 718 (CMM) and $52 745 (IDDS), for an additional cost of $30 027 for IDDS. The mean survival, as treated, was 85.9 days for CMM and 131.8 for IDDS. The cost-effectiveness analysis ratio (CEA) was $239 000 for each additional year of life gained.
As reported in the paper describing early results [2] , complications were infrequent and balanced between the two groups (data not shown), and did not represent a clinical burden.
Discussion
Even when managed according to best practice algorithms [6] and guidelines, 14% of cancer patients have refractory pain [1] , still the most common disabling symptom of cancer [7, 8] . Side-effects of opioids and other pain control medications are common, feared by both patients and physicians, and are important contributors to failure of pain therapy [9] . The Cancer Pain Trial showed that IDDS could better relieve pain with less toxicity, and possibly improve survival in patients with intractable pain after appropriate therapy following approved guidelines [2] .
This 'as treated' analysis more fully illustrates the impact of IDDS. At 4 weeks, 88.5% of IDDS patients achieved clinical success compared with 71.4% (P = 0.02) of non-IDDS patients, and IDDS patients more often achieved > _ 20% reduction in both pain VAS and toxicity (67.3% versus 36.3%; P = 0.0003). By 12 weeks, 22 CMM patients had crossed over to IDDS due to refractory pain or toxicity, improving the values of the remaining non-IDDS group Figure 2 . Reduction in VAS pain scores from baseline at 4 and 12 weeks (as treated). The difference between 'non-IDDS' and 'IDDS' is significant (P = 0.002) at 4 weeks, but the difference narrows at 12 weeks, as CMM patients cross over to IDDS and obtain relief of pain, and the number of patients diminishes (P = 0.23). and lowering the values of the IDDS group: the 'Will Rogers' phenomenon [10] . Despite this, by 12 weeks 82.5% of IDDS patients achieved clinical success compared with 77.8% (P = 0.55) of non-IDDS patients, and more often achieved > _ 20% reduction in both pain VAS and toxicity (57.9% versus 33.3%; P = 0.01). The groups became more similar as the most refractory CMM patients crossed over to IDDS and achieved pain and drug toxicity relief.
At 4 weeks the IDDS VAS pain scores decreased by 60% compared with 37% in non-IDDS patients (P = 0.002). At 12 weeks the IDDS VAS pain scores had decreased by 47%, compared with 42% in the non-IDDS group (P = 0.23). The most refractory group, CMM patients who crossed over and received IDDS implants, had pain VAS reductions of 27%, which was both clinically and statistically significant.
The reduction in drug side-effects in IDDS patients was remarkable. The 4-week drug toxicity scores for IDDS decreased 55%, compared with 20% for the non-IDDS group (P = 0.0003). The 12-week drug toxicity scores for IDDS patients decreased 66%, and for the non-IDDS group by 37% (P = 0.01). All of the individual toxicities were reduced with IDDS. One reason that toxicities were reduced was that the pumps were used to deliver a variety of agents. While morphine is the only drug approved by the FDA for intrathecal delivery, by 4 weeks after implant two-thirds of patients had other drugs in the IDDS, including more lipophilic opioids, local anesthetics, and clonidine. Local anesthetics and clonidine do not have a similar effect when delivered systemically. The most refractory group, CMM patients who crossed over and received IDDS implants, had drug toxicity reductions of 50%, which was both clinically and statistically significant.
Toxicities are one of the most important reasons for non-compliance with pain medicine regimens and poor pain control [9] , and are significant sources of disability and suffering for patients and their families. There is even indirect evidence that opioid toxicities may reduce survival. As early as 1983, animal studies had shown that common side-effects of high-dose opioids in clinically relevant concentrations included immunosuppression and tumor enhancement [11] [12] [13] . More recent animal studies have demonstrated tumor angiogenesis secondary to high-dose opioids [14] with drug levels similar to those obtained with the drug doses used in this trial. Clearly, further research is needed before any definitive statements can be made about causation.
The improved survival observed in the earlier 'as randomized' analysis was associated with assignment to the IDDS study arm and, independently, to reduction in opioid sideeffects within 4 weeks of randomization and improvement in performance status [2] . In this analysis, survival was examined by the treatment actually received, as shown in Figure 6 . It is important to note that survival was not a primary end point of the trial, so all observations must be taken with appropriate caution. Patients who received IDDS therapy had improved survival, with 52%-54% alive at 6 months compared with 32% of the non-IDDS group. The patients who were failed by CMM therapy after randomization and who received IDDS appeared to have similar survival to those who started with IDDS. Explanations for the worse survival of the CMM/no implant group could include pain or drug toxicity, poor prognosis precluding an implant (although performance status does not appear to be different), chance alone, or some combination of the above. Explanations for the relatively good survival of the IDDS/no implant group could include a relatively higher proportion of nociceptive pain, which responds well to CMM, and relatively lower pain scores, as seen in Table 2 ; however, none of these differences were statistically significant. Those who were randomized to IDDS but never received it because their pain and toxicity was controlled had survival equal to those who received IDDS, suggesting that control of symptoms or maintenance of performance status may be one key to better survival. The data are not sufficient to resolve these important questions; unfortunately, the planned replication trial of the North Center Cancer Treatment Group has been cancelled due to concern about low accrual (personal communication, Dr Charles Loprinzi, 4 October 2004). Pain control may be just one type of supportive care that has the potential to improve survival. The results in this trial are similar to preliminary results [15] showing better preserved quality of life, better symptom control, and improved survival of patients randomized to standard oncology care versus standard oncology care with ongoing palliative care consultation (personal communication, Dr John Fenn, 30 January 2003). For pancreas cancer patients with pain undergoing the Whipple procedure, a splanchnic block with alcohol versus placebo significantly improved pain control and survival [16] . A more recent study of similar patients showed that splanchnic block improved pain relief in patients with pancreatic cancer versus optimized systemic analgesic therapy alone. At 1 year, 16% of splanchnic block patients and 6% of opioid-only patients were alive, but the change in survival was not significantly different (P = 0.26, proportional hazards regression) [17] . In a randomized trial of erythropoietin versus placebo for chemotherapy-associated severe anemia, survival was improved with erythropoietin through most time on treatment, with a P-value of 0.13 [18] . In a randomized trial of darbepoetin versus placebo, survival was increased in the darbepoetin group to 46 weeks [95% confidence interval (CI) = 39 to 53 weeks] compared with 34 weeks in the placebo group (95% CI = 29 to 39 weeks) [19] .
The median survival of >100 days for patients who received IDDS would make the IDDS system cost-neutral compared with alternative methods such as an external epidural catheter [20] or home intravenous patient-controlled analgesia, with costs estimated at $4000/month [3] . As reported in preliminary form [5] , the cost-effectiveness analysis ratio of $239 000 would be in the same realm as other expensive supportive care interventions such as bisphosphonates for bone metastases [21] or expensive anti-emetics (reviewed in [22] ). A full cost analysis of the final trial results is in progress.
These data suggest that current oncology practice, even at expert centers, is not optimal, and that such patients can be helped by referral to a pain management team or management by algorithms, in addition to consideration of IDDS. This is an important point to make, and to emphasize that the CMM group received active effective therapy, not 'sham' or ineffective therapy. The 39% improvement in pain control for the CMM control group is strikingly similar to the 25% -40% reduction in pain VAS scores observed by DuPen et al. in the randomized trial of algorithms for pain management in current oncology practice [6] .
In this study, patients randomized to IDDS or who received it after failure of CMM had reduced pain scores, significant relief of most pain control drug toxicities, and possibly improved survival for the duration of this trial. Even the most refractory patients failed by CMM had a 27% reduction in pain scores, a 50% reduction in drug toxicity, and a median survival of >3 months after receiving IDDS. For patients similar to those on this trial, on at least 200 mg of oral morphine or equivalent a day without adequate pain relief or with unmanageable side-effects, IDDS is supported by sufficient evidence [4] to warrant consideration.
